Neuronetics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024
August 12, 2024 at 07:31 am EDT
Share
Neuronetics, Inc. reported earnings results for the second quarter and six months ended June 30, 2024. For the second quarter, the company reported sales was USD 16.45 million compared to USD 17.61 million a year ago. Net loss was USD 9.83 million compared to USD 4.9 million a year ago. Basic loss per share from continuing operations was USD 0.33 compared to USD 0.17 a year ago.
For the six months, sales was USD 33.87 million compared to USD 33.15 million a year ago. Net loss was USD 17.71 million compared to USD 15.42 million a year ago. Basic loss per share from continuing operations was USD 0.59 compared to USD 0.54 a year ago.
Neuronetics, Inc. is a commercial-stage medical technology company. The Company is focused on designing, developing and marketing products for patients who suffer from neurohealth disorders. Its commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation (TMS) to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The NeuroStar Advanced Therapy System is used to treat adult patients with major depressive disorder (MDD). The Company intends to continue to pursue development of its NeuroStar Advanced Therapy System for additional indications. The Company sells its NeuroStar Advanced Therapy System and recurring treatment sessions in the United States. Its primary focus is on selling to psychiatrists, with primary care physicians and pain management specialists.
NEURONETICS, INC. 
